The quality of investigational drug pivotal studies would be enhanced by requiring FDA review of Phase III protocols and making the agency’s recommendations binding on sponsors, researchers say in the Journal of the American Medical Association.
Mandatory FDA Review Of Pivotal Trial Protocols Urged In JAMA
Dartmouth researchers say that although FDA recommendations can strengthen study designs and improve outcome measures, sponsors often don’t follow agency’s advice or don’t even seek input in Phase III design.